Biomedtracker and QLS Advisors Present the NEW Predictive Probability of Approval (POA) Metric Pilot in Biomedtracker for all indications!

Click here to see it in action! 

Drug development is challenging. Improve your risk-reward ratio and identify promising assets in less time by leveraging the Probability of Approval– a new perspective on drug success!

• QLS POA is driven by a robust machine learning algorithm incorporating over 200+ drug, trial, sponsor, and indication-specific features (derived from Informa’s leading clinical data sets).
• QLS POA metrics work alongside BMT’s industry-renowned Likelihood of Approval to help you aggregate powerful analyst-derived insights with transparent data-driven statistical approval metrics.
• Dive into the underlying logic and key impact drivers for each drug asset in development using the new POA feature pages – now available for all disease groups!
• Check out this new pilot feature found on drug, indication pages and the Advanced Drug Search (as a filter). Please let us know your feedback!